# Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

> **NCT01984294** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 101 (actual)

## Conditions studied

- Chronic HCV Infection

## Interventions

- **DRUG:** LDV/SOF
- **DRUG:** RBV
- **DRUG:** GS-9669

## Key facts

- **NCT ID:** NCT01984294
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-04
- **Final completion:** 2014-07
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2018-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01984294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01984294, "Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01984294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*